Reactive astrocytes surrounding GBM lesions produce connective tissue growth factor (CTGF), fostering tumor growth, migration, and invasion, suggesting CTGF inhibition as a potential therapeutic avenue. This evidence concerns the gene CCN2 and glioblastoma.